Evidence map›Paper›PMID 38304028›Full record

ArticleFrontiers in oncology2023

Positive response to trastuzumab deruxtecan in a patient with HER2-mutant NSCLC after multiple lines therapy, including T-DM1: a case report.

Junzhu Xu, Bo He, Yunan Wang, Mengjia Wu, Yanyi Lu, Zixuan Su, Shujun Liu, Fengmin Yin, Jian-Guo Zhou, Wei Hu

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Junzhu XuDepartment of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Bo HeDepartment of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Yunan WangDepartment of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Mengjia WuDepartment of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Yanyi LuDepartment of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Zixuan SuDepartment of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Shujun LiuDepartment of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Fengmin YinDepartment of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Jian-Guo ZhouDepartment of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Wei HuDepartment of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Rutgers, The State University of New Jersey · USJohns Hopkins University · USAlbert Einstein College of Medicine · USHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human epidermal growth factor 2 (

Indexed as

ADCSchemotherapyHER2 mutationnon-small cell lung cancertarget-therapyT-DXd

Identifiers

PMID38304028
PMCPMC10830643
OpenAlexW4390983149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.